Search - tctmd.com

Displaying 1 - 20 of 98

Sort: Relevancy | Date

News Conference News ACC 2025

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Yael L. Maxwell

April 07, 2025

News Conference News ACC 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

Caitlin E. Cox

April 02, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

News Conference News ACC 2024

Oral Device Noninferior to CPAP for Reducing BP in Sleep Apnea: CRESCENT

Caitlin E. Cox

April 06, 2024

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Todd Neale

March 10, 2023

News Conference News ACC 2023

‘Causal AI’ May Help Guide Specific Actions to Reduce CVD Risk

Caitlin E. Cox

March 10, 2023

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Conference News ACC 2023

Wrist-Worn Sensor May Help Detect Elevated Troponin in ACS

L.A. McKeown

March 06, 2023

News Conference News ACC 2023

Free Meds Don’t Reduce CV Events, but Tailored Messaging Does: ACCESS

Caitlin E. Cox

March 05, 2023

Presentation ACC 2023

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Presenter: Christie Ballantyne

March 05, 2023

News Conference News ACC 2023

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

Caitlin E. Cox

March 04, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

Advertisement

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

WARRIOR: No Clear Answers on How to Best Treat INOCA

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Oral Device Noninferior to CPAP for Reducing BP in Sleep Apnea: CRESCENT

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

What’s Going to Be Hot at ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

‘Causal AI’ May Help Guide Specific Actions to Reduce CVD Risk

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Wrist-Worn Sensor May Help Detect Elevated Troponin in ACS

Free Meds Don’t Reduce CV Events, but Tailored Messaging Does: ACCESS

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content